Published 3 days ago • loading... • Updated 3 days ago

Brii Bio Unveils New Data from Its Ongoing Phase 2 ENSURE Study at APASL 2025, Showcasing BRII-179's Unique Potential to Prime and Boost Higher HBsAg Loss Through Target Patient Identification

On March 30, 2025, Brii Biosciences Limited announced new data from the ongoing Phase 2 ENSURE study at the 34th Annual Meeting of the Asian Pacific Association for the Study of the Liver in Beijing, China, highlighting findings related to BRII-179 and elebsiran .
The ENSURE study aims to address the high unmet medical needs of the 254 million people globally infected with chronic Hepatitis B virus , a leading cause of liver disease, by evaluating novel therapeutic strategies.
The ENSURE study, a multicenter, open-label Phase 2 trial, includes cohorts evaluating elebsiran's contribution in combination with PEG-IFN and a novel enrichment strategy utilizing BRII-179 to identify immune responders among participants with chronic HBV infection and baseline HBsAg levels of 100-3,000 IU/mL.
According to Dr. Grace Lai-Hung Wong, Professor of Gastroenterology and Hepatology at CUHK Medical Data Analytics Centre , "The positive Cohort 4 data from the ENSURE study opens new doors for HBV functional cure,", while David Margolis, Chief Medical Officer of Brii Bio, stated that Cohort 4 continues to support their enrichment strategy for developing a functional cure for chronic HBV.
Emerging data from Cohort 4 revealed that 55.6% of BRII-179 responders achieved HBsAg seroclearance at Week 24, compared to 10.0% of non-responders, suggesting BRII-179's potential as a predictive tool and supporting the combination of elebsiran and PEG-IFN as generally safe and well-tolerated in virally suppressed chronic HBV patients, with treatment ongoing for 48 weeks.

Insights by Ground AI

Does this summary seem wrong?

24 Articles

All

Left

Center

Right

Rutland Herald

+21 Reposted by 21 other sources

Center

Brii Bio Unveils New Data from Its Ongoing Phase 2 ENSURE Study at APASL 2025, Showcasing BRII-179's Unique Potential to Prime and Boost Higher HBsAg Loss Through Target Patient Identification

Preliminary data from Cohort 4 of the ENSURE study supports a novel enrichment strategy to utilize BRII-179 to identify patients who are immune responders and have the potential to achieve higher HBsAg loss at EOT48-week EOT data from Cohort 1-3…

3 days ago

Read Full Article

Macau Business

Brii Biopharma presents new data from its ongoing Phase 2 ENSURE study at the 2025 Asia Pacific Association for the Study of the Liver, demonstrating the potential of BRII-179 to improve HBsAg clearance through targeted patient identification

Preliminary data from ENSURE cohort 4 support a novel enrichment strategy using BRII-179 to identify immune-responsive patients with the potential to achieve higher HBsAg clearance at end of treatment (EOT) Week 48 EOT data from ENSURE cohorts 1-3 clearly demonstrate the additional benefit of elebsiran plus PEG-IFNα therapy to achieve higher HBsAg clearance rates BEIJING, China and DURHAM, N.C., March 30, 2025 /PRNewswire/ -- Brii Biopharma Inc.…

3 days ago

Read Full Article